Skip to main content
Premium Trial:

Request an Annual Quote

Quest Deal for Celera Clears US Antitrust Review

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics today said that its proposed acquisition of Celera has cleared US antitrust review.

The firm said that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired in connection with the deal, satisfying one of the conditions necessary to close the transaction.

Quest made the offer last month to acquire Celera for $8 per share. The total value of the deal is $671 million, or $344 million net of cash and short-term investments.

The firms said today that the offer is still scheduled to expire at 5:00 p.m., New York City time on April 25, unless it is extended. However, the deal has been challenged by certain shareholders, who believe the purchase price does not adequately value Celera's assets.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.